SEARCH:   Advanced

Blood, 1 January 2006, Vol. 107, No. 1, pp. 285-292. Prepublished online as a Blood First Edition Paper on September 1, 2005; DOI 10.1182/blood-2005-06-2208. This Article Full Text (PDF) All Versions of this Article: 2005-06-2208v1 107/1/285    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Costa, L. F Articles by Cardoso, A. A Search for Related Content PubMed PubMed Citation Articles by Costa, L. F Articles by Cardoso, A. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 2, 2005 Accepted August 22, 2005 Pro-angiogenic stimulation of bone marrow endothelium engages mTOR, and is inhibited by simultaneous blockade of mTOR and NF-B Lara F Costa, Mercedes Balcells, Elazer R Edelman, Lee M Nadler, and Angelo A Cardoso* Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA; Institut Quimic de Sarria, Barcelona, Spain Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA * Corresponding author; email: cardoso{at}mbcrr.harvard.edu. Most bone marrow (BM) malignancies develop in association with an angiogenic phenotype and increased numbers of endothelial cells. The molecular mechanisms involved in the modulation and recruitment of BM endothelium are largely unknown, and may provide novel therapeutic targets for neoplastic diseases. We observed that angiogenic stimulation of BM endothelial cells activates mTOR and engages its downstream pathways 4E-BP1 and S6K1, which are inhibited by the mTOR-specific blockers Rapamycin and CCI-779. Both mTOR blockers significantly inhibit growth factor- and leukemia-induced proliferation of BM endothelium by inducing G0/G1 cell cycle arrest. This effect is associated with downregulation of cyclin D1 and cdk-2-phosphorylation, and upregulation of the cdk-inhibitors p27kip1 and p21cip1. Under conditions that reproduce the biomechanical fluidic environment of the BM, CCI-779 is equally effective in inhibiting BM endothelial cell proliferation. Finally, simultaneous blockade of mTOR and NF-B pathways synergize to significantly inhibit or abrogate the proliferative responses of BM endothelial cells to mitogenic stimuli. This study identifies mTOR as an important pathway for the pro-angiogenic stimulation of BM endothelium. Modulation of this pathway may serve as a valid therapeutic intervention in BM malignancies evolving in association with an angiogenic phenotype. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. SHIRASO, Y. KATAYOSE, K. YAMAMOTO, M. MIZUMA, S. YABUUCHI, A. ODA, T. RIKIYAMA, T. ONOGAWA, H. YOSHIDA, H. HAYASHI, et al. Overexpression of Adenovirus-mediated p27kip1 Lacking the Jab1-binding Region Enhances Cytotoxicity and Inhibits Xenografted Human Cholangiocarcinoma Growth Anticancer Res, June 1, 2009; 29(6): 2015 - 2024. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020